Scinopharm Taiwan, Ltd. (1789) Stock Price & Analysis
1789 Stock Chart & Stats
- Day’s Range
- TWD 18.35 - TWD 20.40
- 52-Week Range
- TWD 16.70 - TWD 29.10
- Previous Close
- TWD 19.45
- Volume
- N/A
- Average Volume (3M)
- 476.43K
- Market Cap
- TWD 15.93B
- Enterprise Value
- TWD 13.70B
- Total Cash (Recent Filing)
- TWD 3.50B
- Total Debt (Recent Filing)
- TWD 873.09M
- Price to Earnings (P/E)
- 898.2
- Beta
- 0.32
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 02, 2026
- Dividend Yield
- 1.44%
1789 FAQ
What was Scinopharm Taiwan, Ltd.’s price range in the past 12 months?
What is Scinopharm Taiwan, Ltd.’s market cap?
When is Scinopharm Taiwan, Ltd.’s upcoming earnings report date?
How were Scinopharm Taiwan, Ltd.’s earnings last quarter?
Is Scinopharm Taiwan, Ltd. overvalued?
Does Scinopharm Taiwan, Ltd. pay dividends?
What is Scinopharm Taiwan, Ltd.’s EPS estimate?
How many shares outstanding does Scinopharm Taiwan, Ltd. have?
What happened to Scinopharm Taiwan, Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Scinopharm Taiwan, Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Scinopharm Taiwan, Ltd.
ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceutical clients throughout Taiwan, the United States, Europe, India, various parts of Asia, and other international regions. Its service offerings include custom synthesis for biochemical molecules like peptides and nucleic acids, manufacturing of generic APIs, and comprehensive outsourcing solutions. ScinoPharm also provides Contract Research and Manufacturing (CRAM) services, which involve chemistry expertise, analytical and regulatory support, chemical process development, clinical drug substance manufacturing, and consulting. These CRAM services facilitate the creation and production of APIs and intermediates for clinical, small-scale, and commercial applications. Moreover, the company actively develops advanced peptide synthesis technologies. ScinoPharm is involved in the development and manufacturing of a diverse range of products, such as Western medicines, various chemical materials, albumin-based drugs, oligonucleotide medicines, injectables, and novel small molecule drugs, alongside offering biotechnology and technical services. The company holds a strategic alliance with Baxter International Inc. focused on the joint development, production, and commercialization of an antiemetic drug for cancer chemotherapy. ScinoPharm Taiwan, Ltd. was founded in 1997 and has its headquarters in Tainan City, Taiwan.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Li-An Lu
- Employees
- 1,010
- Website
- www.scinopharm.com/tw
- Address
- No. 1, Nan-Ke 8th Road, Tainan City, TQ, 741014, TW
Scinopharm Taiwan, Ltd. (1789) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 11 | 0 | 1 |

